Asset
LB-102
LB Pharmaceuticals Inc Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07369154 | phase3 | recruiting | 2026-04-23 | 2028-12-01 | LB Pharmaceuticals Inc. | 52-week Open Label Safety-Tolerability Study |
| NCT07494305 | phase2 | recruiting | 2026-01-23 | 2028-02-01 | LB Pharmaceuticals Inc. | Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE. |
| NCT06179108 | phase2 | completed | 2023-11-29 | 2024-12-04 | LB Pharmaceuticals Inc. | Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia |
| NCT04588129 | phase1 | completed | 2021-01-05 | 2021-09-17 | LB Pharmaceuticals Inc. | Receptor Occupancy of LB-102 Using Positron Emission Tomography (PET) in Healthy Volunteers |
| NCT04187560 | phase1 | completed | 2020-01-22 | 2020-07-01 | LB Pharmaceuticals Inc. | Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults |
FDA applications (0)
This company has no applications containing this asset.